title: When Should Ribavirin Be Started to Treat Hepatitis E Virus Infection in Transplant Patients?
authors.affiliation: Department of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, France.|INSERM U1043, IFR-BMT, CHU, Purpan, Toulouse, France.|Université Paul Sabatier, Toulouse, France.
authors.forename: N
authors.initials: N
authors.lastname: Kamar
authors.affiliation: Department of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, France.
authors.forename: O
authors.initials: O
authors.lastname: Marion
authors.affiliation: INSERM U1043, IFR-BMT, CHU, Purpan, Toulouse, France.|Université Paul Sabatier, Toulouse, France.|Laboratory of Virology, CHU Purpan, Toulouse, France.
authors.forename: J
authors.initials: J
authors.lastname: Izopet
mesh_terms: D005260:Female; D016751:Hepatitis E / Q000145:classification*; D016752:Hepatitis E virus / Q000302:isolation & purification*; D006801:Humans; D016031:Liver Transplantation / Q000009:adverse effects*; D019562:Viral Load
keywords: clinical research/practice; infection and infectious agents; infectious disease; liver disease; viral: hepatitis